Article
MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.
Cancer discovery - 1 Sept 2016
Pietrantonio Filippo, Oddo Daniele, Gloghini Annunziata, Valtorta Emanuele, Berenato Rosa, Barault Ludovic, Caporale Marta, Busico Adele, Morano Federica, Gualeni Ambra Vittoria, Alessi Alessandra, Siravegna Giulia, Perrone Federica, Di Bartolomeo Maria, Bardelli Alberto, de Braud Filippo, Di Nicolantonio Federica
Abstract excerpt
UNLABELLED: A patient with metastatic BRAF-mutated colorectal cancer initially responded to combined EGFR and BRAF inhibition with panitumumab plus vemurafenib. Pre-existing cells with increased MET gene copy number in the archival tumor tissue likely underwent clonal expansion during treatment, leading to the emergence of MET amplification in the rebiopsy taken at progression. In BRAF-mutated colorectal cancer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.